Patient tolerance study of topical chlorhexidine diphosphanilate: a new topical agent for burns.
Effective topical antimicrobial agents decrease infection and mortality in burn patients. Chlorhexidine phosphanilate (CHP), a new broad-spectrum antimicrobial agent, has been evaluated as a topical burn wound dressing in cream form, but preliminary clinical trials reported that it was painful upon application. This study compared various concentrations of CHP to determine if a tolerable concentration could be identified with retention of antimicrobial efficacy. Twenty-nine burn patients, each with two similar burns which could be separately treated, were given pairs of treatments at successive 12-h intervals over a 3-day period. One burn site was treated with each of four different CHP concentrations, from 0.25 per cent to 2 per cent, their vehicle, and 1 per cent silver sulphadiazine (AgSD) cream, an antimicrobial agent frequently used for topical treatment of burn wounds. The other site was always treated with AgSD cream. There was a direct relationship between CHP concentration and patients' ratings of pain on an analogue scale. The 0.25 per cent CHP cream was closest to AgSD in pain tolerance; however, none of the treatments differed statistically from AgSD or from each other. In addition, ease of application of CHP creams was less satisfactory than that of AgSD. It was concluded that formulations at or below 0.5 per cent CHP may prove acceptable for wound care, but the vehicle system needs pharmaceutical improvement to render it more tolerable and easier to use.
Miller
L M
LM
Regional Burn Center, University of California, San Diego Medical Center.
Loder
J S
JS
Hansbrough
J F
JF
Peterson
H D
HD
Monafo
W W
WW
Jordan
M H
MH
D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D002056:Burns / Q000188:drug therapy*; D002710:Chlorhexidine / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D004311:Double-Blind Method; D004643:Emollients / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D008875:Middle Aged; D010146:Pain / Q000139:chemically induced / Q000175:diagnosis; D014677:Pharmaceutical Vehicles; D011897:Random Allocation; D012837:Silver Sulfadiazine / Q000008:administration & dosage / Q000627:therapeutic use; D013997:Time Factors; D014946:Wound Infection / Q000517:prevention & control
D004643:Emollients; D014677:Pharmaceutical Vehicles; D002710:Chlorhexidine; D012837:Silver Sulfadiazine